Suppliers / Astrea Fontaine

Astrea Fontaine

France Updated 9 July 2026

Astrea Fontaine is a finished-dose manufacturer based in France. It appears in 5 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with EDE (AE), ARCSA (EC) and UZPHARM (UZ). Its GMP standing is certified by ANSM (FR), ANVISA (Brazil) and MFDS (Korea), among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 13 September 2024 as VAI.

0
active US DMFs
0
valid CEPs
4
registered plants 1 with an FDA FEI number
5
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 13 September 2024 VAI US FDA
  • 11 December 2020 VAI US FDA
  • 10 November 2017 VAI US FDA
  • 22 January 2016 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Fontaine Les Dijon, United Arab Emirates Not on file
Fontaine-Les-Dijon, France Not on file
FONTAINE LES DIJON, France Not on file
France, France 3002807473

Filings and GMP by regulator

Regulator Filings GMP certificates
EDE (AE) 3 None
ARCSA (EC) 1 None
UZPHARM (UZ) 1 None
ANSM (FR) None 9
ANVISA (Brazil) None 4
MFDS (Korea) None 2
EMA None 1
US FDA None 1

Scale

Year Revenue Exports Destinations
2024 $42.3M Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Astrea Fontaine comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 13 September 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported